The clinical diagnosis of acute pancreatitis is set by a combination of symptoms (abdominal pain) and increased blood levels of pancreatic enzymes (i.e. amylase and lipase). The most common complication of Endoscopic Retrograde Cholangio-Pancreatography (ERCP) is acute pancreatitis (7%, Freeman et al 1996). Increased blood levels of amylase and lipase is seen in 25-40% of cases after ERCP (Tsujino et al 2005).
Conditions
Interventions
Trade Name: Cozaar
Pharmaceutical Form: Capsule*
INN or Proposed INN: losartan
CAS Number: 124750-99-8
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 50-
Pharmaceu
Sponsors
Unit of Esophageal and Gastric Research Dep. of Molecular Medicine and Surgery Karolinska Institutet
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Informed consent from patients planned for ERCP. Over 18 years of age. No ERCP during the last year Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Under 18 years of age Pregnant or nursing women Patient not able to informed consent Patient taking AT1- or ACE-inhibitor Patient with current acute pancreatitis Patient with clinical acute pancreatitis DIC, severe sepsis or shock Dehydration, hypovolemia or hypotension (<100-110 mm Hg systolic Blood Pressure Known hypersensitivity or allergia to Cozaar Severe liver cirhosis Severe renal insuffiency (Crea <10 ml/min) or in dialysis Bilateral renal artery stenosis or single renal stenosis in case of single-kidney patient
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To elucidate wether prophylactic treatment with Cozaar can reduce enzyme level of lipase and amylase after ERCP;Secondary Objective: To evaluate the efficacy of Cozaar on reducing incidence of acute pancreatitis after ERCP;Primary end point(s): Measurement of lipase / amylase level at baseline, 4h and 18 h respectively after the procedure. Analysis of pain 24 h after procedure. Blood glucose level 4 h after procedure. Blood pressure monitoring until 6 h after intake of Cozaar. | — |
Countries
Sweden
Outcome results
None listed